Switching advanced meds for Crohn's or colitis
Part of Digestive system clinical trials.
This trial looks at people with Crohn's disease or ulcerative colitis who have already tried and failed at least one advanced medication (like a biologic or small molecule drug). If you are starting a new advanced therapy, researchers will track how well it works for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with Crohn's disease or ulcerative colitis for at least 3 months.
- You have already tried and failed at least one advanced (biologic or small molecule) treatment for your IBD.
- You have started a new advanced therapy within the past 1 to 8 weeks for your IBD.
- You are willing to sign a consent form to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a diet and stress management program to standard advanced therapy helps people with active Crohn's disease or ulcerative colitis feel better. It combines lifestyle changes with new medications to improve treatment outcomes.
This trial tests new therapies for people with moderate to severe Crohn's disease or ulcerative colitis. It may help if your standard treatments aren't working well enough.
This study tests a new medication called BI 3032950 for people with ulcerative colitis who have already tried other advanced treatments (biologics or targeted therapies) that didn't work well enough or caused problems. The goal is to see if the new drug is safe and helps control inflammation in the colon.
This trial tests whether adding a special liquid diet (partial enteral nutrition) to a new advanced Crohn's medication can help control disease better than the medication alone.
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
This study looks at blood and/or tissue “molecular” (cell-level) reasons why treatments don’t fully work in adults with Crohn’s disease or ulcerative colitis. If you are starting a biologic or small-molecule medicine and still have moderate to severe symptoms, you may be able to contribute to research that helps improve future care.
Hear when a new IBD (Inflammatory Bowel Disease) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.